Hemab Therapeutics Holdings, Inc. Common Stock(COAG)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
2-STAR RATING
Consider higher Upturn Star rating
BUY for 9 days
PROFIT SINCE LAST BUY
-5.2% ▼
LAST CLOSE
$40.86
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for COAG

11/13/2026: COAG (2-star) has a low Upturn Star Rating. Not recommended to BUY.

Hemab Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing prophylactic antibody therapies for rare and severe blood coagulation disorders. The company's primary strength lies in its specialized pipeline of differentiated assets like sutacimig (HMB-001) and HMB-002, which address significant unmet needs in bleeding disorders. Its core investment story centers on high-growth potential driven by upcoming clinical milestones, backed by cash reserves secured from its 2026 public market debut. However, the company faces substantial execution risks, zero commercial revenue, and typical pre-commercial biotechnology volatility. This stock suits growth-oriented investors with high risk tolerance, who should closely monitor clinical trial readouts and regulatory updates.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorStrong fitThe company offers high-growth potential driven by clinical-stage rare disease drug development milestones.
Momentum investorStrong fit while signal remains positiveShort-term price action responds dynamically to clinical data readouts and broader biotech sector momentum.
Value investorWeak fitThe absence of commercial revenue and current earnings makes traditional value metrics inapplicable.
Dividend investorWeak fitThe company pays no dividends and retains all capital to fund clinical research.
Low-risk investorWeak fitHigh clinical development risks and share price volatility present substantial risk for conservative investors.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighClinical-stage biotechnology stocks frequently experience sharp price swings around clinical updates and market conditions.
Valuation riskMedium / highValuation relies heavily on future clinical success and regulatory approvals rather than current earnings.
Competition risk (rare disease and gene therapy competition)Medium / highWell-funded competitors are constantly developing alternative therapies for rare bleeding disorders.
Business qualityMediumThe science is promising, but the business lacks commercial-stage validation or diversified revenue streams.
Dividend incomeLow / noneNo dividend is paid or anticipated in the near term.
Execution riskHighSuccess depends entirely on cleanly executing complex clinical trials and securing regulatory approvals.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.91B USD
Price to earnings Ratio -
1Y Target Price 63
Price to earnings Ratio -
1Y Target Price 63
Volume (30-day avg) 479.0K shares
Beta -
52 Weeks Range 18.00 - 55.42
Updated Date 11/15/2026
52 Weeks Range 18.00 - 55.42
Updated Date 11/15/2026
Dividends yield (FY) -
Basic EPS (TTM) -3.55

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Biotechnology

BUY participation
45.5%
Active BUY / eligible
20 / 44
30-Day BUY Count Change
+13

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit 30.06%
Avg. Invested days 29
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 3.0
Stock Returns Performance Upturn Returns Performance icon 3.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
COAG receives a 3-star rating, supported by solid analyst coverage. The rating is constrained by weak unit economics, and weak price momentum.

Company Fundamentals

★★★★★
COAG has moderate overall fundamentals (3 stars), with moderate financial health, soft growth momentum, and solid ownership. In FY2025 versus FY2024, growth and ownership metrics are mixed: negative earnings growth (-31.2%), soft cash generation (FCF margin 0.0%), slightly negative revenue growth (+0.0%).

Financial Health Rating

★★★★★
COAG's financial health is supported by strong efficiency, including operating-expense and cost-of-revenue discipline (opex 0.0% of revenue). Profitability is weak (1 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
COAG's growth profile is soft, with the least-weak measure being revenue growth at +0.0% FY2025 versus FY2024. By comparison, while earnings growth (-31.2%, negative) and free-cash-flow growth (-34.0%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 98.0% and approximately 38.4% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 11.00% supports management-shareholder alignment.

Top 5 Institutional Investors

RA Capital Management, LLC 16.71%
Novo A/S 8.95%
FMR Inc 7.91%
Deep Track Capital, LP 7.71%
Capital Research & Mgmt Co - Division 3 7.71%

Unit Economics (Per $1K Revenue)

★★★★★
COAG generates approximately $0 of gross profit, $-0 of operating income, and $-0 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Weak margins explain the 1-star rating, with weak cash conversion and strong capital efficiency.

Economic Dimensions

★★★★★
Effective Tax Rate: 0.35%

Quantitative Style Profile

★★★★★
COAG has a relatively low-volatility profile. Weak momentum is the primary drawback.

Style Classification

Quality Focused

Low VolatilitySmall / Mid Cap Risk

How Company Makes Money

Business areaWhat it includesRetail investor read
Therapeutic Licensing and Commercialization (Future)Anticipated future revenue from commercialized proprietary antibody therapeutics and potential milestone or royalty payments from licensing agreements.The company currently generates no revenue and relies on equity financing while advancing its drug candidates toward market approval.

Valuation

Trailing PE -
Forward PE -
Enterprise Value 1.48B
Price to Sales(TTM) -
Enterprise Value 1.48B
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 46.73M
Shares Floating 17.96M
Shares Outstanding 46.73M
Shares Floating 17.96M
Percent Insiders 11
Percent Institutions 97.98

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.